文献速递青光眼眼底病与葡萄膜炎

玻璃体内注射非选择性ANGPT1/2抗体快速诱发青光眼:ANGPT/TIE2信号在灵长类房水流出中的潜在作用

Rapid Development of Glaucoma Via ITV Nonselective ANGPT 1/2 Antibody: A Potential Role for ANGPT/TIE2 Signaling in Primate Aqueous Humor Outflow.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

在成年猴中玻璃体内注射抗VEGF/ANGPT F(ab')2(同时阻断ANGPT1和ANGPT2)后,1.5和4 mg/眼组全部出现眼压升高,并伴视盘凹陷和神经视网膜边缘变薄;组织病理显示1.5 mg/眼及以上剂量组出现不可逆视神经轴索变性,考虑继发于高眼压。单独抗ANGPT Fab也升高眼压,而抗VEGF Fab不贡献眼压升高;抗ANGPT2选择性抗体不改变眼压。小鼠中同时阻断ANGPT1和ANGPT2可损害Schlemm管血管扩张和形成,类似Angpt1/Angpt2及其受体TIE2基因敲除。

要点

  • 猴玻璃体内注射抗VEGF/ANGPT F(ab')2后,1.5和4 mg/眼组全部出现眼压升高并伴青光眼性损害。
  • 抗ANGPT Fab也升高猴眼压,抗VEGF Fab不贡献眼压升高,抗ANGPT2选择性抗体不改变眼压。
  • 小鼠同时阻断ANGPT1和ANGPT2损害Schlemm管血管扩张和形成,单独阻断ANGPT2不影响。

核心结论

  • 同时抑制ANGPT1/ANGPT2(而非单独抑制ANGPT2)导致猴眼压升高和青光眼性损害。
  • 这证实TIE2/ANGPT信号在成年动物眼压控制中的作用,该发现最初在转基因小鼠中识别。
  • 同时药物性抑制ANGPT1/ANGPT2可能影响成年猴房水引流和稳态,并可能有助于开发新型青光眼模型。

研究设计与样本

  • 在猴中开展玻璃体内抗VEGF/ANGPT F(ab')2(同时阻断ANGPT1和ANGPT2)的眼部耐受性研究。
  • 在新生小鼠中开展机制研究。

主要发现

  • 第二次玻璃体内注射抗VEGF/ANGPT F(ab')2后,所有1.5和4 mg/眼治疗的猴均出现眼压升高,最终与视盘凹陷和神经视网膜边缘变薄相关。
  • 组织病理学检查显示,给予1.5 mg/眼及以上剂量的动物视神经出现不可逆轴索变性,被认为继发于高眼压。
  • 抗ANGPT Fab也导致猴眼压升高,但抗VEGF Fab不贡献眼压升高。
  • 抗ANGPT2选择性抗体不改变眼压。
  • 小鼠中同时阻断ANGPT1和ANGPT2损害Schlemm管血管的扩张和形成,类似Angpt1/Angpt2及其受体TIE2的基因敲除;如先前报道,单独阻断ANGPT2不影响小鼠Schlemm管形成。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Investigate a significant, dose-related increase in IOP, leading to glaucomatous damage to the neuroretina and optic nerve following intravitreal (ITV) administration of a bispecific F(ab')2 [anti-VEGF/Angiopoietins [ANGPT]F(ab')2] molecule in adult monkeys. METHODS: ITV ocular tolerability and investigation of anti-VEGF/ANGPT F(ab')2 (blocking both ANGPT1 and ANGPT2) was done in monkeys; mechanistic studies were done in neonatal mice. RESULTS: Following the second ITV dose of anti-VEGF/ANGPT F(ab')2, all 1.5- and 4-mg/eye treated monkeys developed elevated IOP, which eventually was associated with optic disc cupping and thinning of the neuroretinal rim. Histopathologic examination showed nonreversible axonal degeneration in the optic nerves of animals administered 1.5 mg/eye and higher that was considered secondary to high IOP. Anti-ANGPT Fab also caused elevated IOP in monkeys, but anti-VEGF Fab did not contribute to the IOP increase. In addition, an anti-ANGPT2-selective antibody did not change IOP. In mice simultaneous blockade of ANGPT1 and ANGPT2 impaired the expansion and formation of Schlemm's canal (SC) vessels, similar to genetic ablation of Angpt1/Angpt2 and their receptor TIE2. As previously reported, blocking ANGPT2 alone did not affect SC formation in mice. CONCLUSIONS: Dual inhibition of ANGPT1/ANGPT2, but not ANGPT2 alone, leads to increased IOP and glaucomatous damage in monkeys. This confirms a role for TIE2/ANGPT signaling in the control of IOP in adults, a finding initially identified in transgenic mice. Dual pharmacologic inhibition of ANGPT1/ANGPT2 may affect aqueous drainage and homeostasis in adult monkeys and may be useful in developing novel models of glaucoma.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Thackaberry EA, Zhou Y, Zuch de Zafra CL, et al. Rapid Development of Glaucoma Via ITV Nonselective ANGPT 1/2 Antibody: A Potential Role for ANGPT/TIE2 Signaling in Primate Aqueous Humor Outflow. Invest Ophthalmol Vis Sci. 2019. PMID: 31574535. doi:10.1167/iovs.18-26349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。